Novel CAR-T Cell Therapy for Relapsed Lymphoma

A phase 1/2 study evaluating a novel chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of therapy.

Trial Details

NCT ID
NCT06345678
Phase
Phase 1 / Phase 2
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Cancer Type
Lymphoma
Locations (sample)
  • Bethesda, Maryland
  • Houston, Texas

Key Eligibility Criteria

  • Age 18 to 75 years
  • Relapsed or refractory diffuse large B-cell lymphoma
  • At least 2 prior lines of systemic therapy
  • ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →